The agent used most widely to treat women with breast cancer is the triphenylethylene antiestrogen, trans-tamoxifen (TAM), which continues to undergo extended trials as an adjuvant therapy in estrogen receptor (ER) positive pre- and post-menopausal patients. Although it is known that TAM interferes with hormonal induction of specific genes, the exact biochemical mechanisms by which this occurs are not understood. Transcription is enhanced after estradiol (E2) and a dimeric ER protein form a complex at a specific site on DNA, called an estrogen responsive element (ERE), near the promoter of a responsive gene. 4- Hydroxytamoxifen (4-OHT), an active metabolite of TAM, binds to the ligand site of ER, but as results from our laboratory and others suggest, the conformation of the ER is altered compared to that of E2-ER. One of our observations is that at saturation, the apparent molar amount of 4- OHT-ER that can bind to either isolated cell nuclei, or plasmids bearing EREs, is only about half that of E2-ER. Among the explanations that we will evaluate is that a conformational change induced upon 4-OHT-ER-ERE complex formation, allows binding of only one, instead of the normal two, ligands per ER dimer. When several ERE sequences are in tandem, E2-ER binds cooperatively, but 4-OHT-ER does not, indicating that the conformational alteration in ER influences ER-ER interaction during DNA binding. Preliminary results show that antibodies to the DNA binding domain of ER can differentially inhibit E2-ER vs. 4-OHT-ER binding, revealing details of the conformational change. Additional results demonstrate that 4-OHT-ER dissociates more slowly from EREs than E2-ER. Further information will be obtained by DNA footprint analysis. The role of ERE sequence, spacing and stereoalignment on ER-DNA binding parameters will also be determined. The effect of these changes in EREs on promoter induction will be evaluated by transfection analyses. Overall, results will reveal structural and mechanistic consequences of 4-OHT binding to the ER.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project (R01)
Project #
2R01HD024459-04
Application #
3325055
Study Section
Reproductive Endocrinology Study Section (REN)
Project Start
1990-01-01
Project End
1996-12-31
Budget Start
1993-01-01
Budget End
1993-12-31
Support Year
4
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Rochester
Department
Type
Schools of Dentistry
DUNS #
208469486
City
Rochester
State
NY
Country
United States
Zip Code
14627
Huang, Jing; Li, Xiaodong; Maguire, Casey A et al. (2005) Binding of estrogen receptor beta to estrogen response element in situ is independent of estradiol and impaired by its amino terminus. Mol Endocrinol 19:2696-712
Li, Xiaodong; Huang, Jing; Yi, Ping et al. (2004) Single-chain estrogen receptors (ERs) reveal that the ERalpha/beta heterodimer emulates functions of the ERalpha dimer in genomic estrogen signaling pathways. Mol Cell Biol 24:7681-94
Huang, Jing; Li, Xiaodong; Yi, Ping et al. (2004) Targeting estrogen responsive elements (EREs): design of potent transactivators for ERE-containing genes. Mol Cell Endocrinol 218:65-78
Yi, Ping; Driscoll, Mark D; Huang, Jing et al. (2002) The effects of estrogen-responsive element- and ligand-induced structural changes on the recruitment of cofactors and transcriptional responses by ER alpha and ER beta. Mol Endocrinol 16:674-93
Yi, Ping; Bhagat, Sumedha; Hilf, Russell et al. (2002) Differences in the abilities of estrogen receptors to integrate activation functions are critical for subtype-specific transcriptional responses. Mol Endocrinol 16:1810-27
Sathya, Ganesan; Yi, Ping; Bhagat, Sumedha et al. (2002) Structural regions of ERalpha critical for synergistic transcriptional responses contain co-factor interacting surfaces. Mol Cell Endocrinol 192:171-85
Muyan, M; Yi, P; Sathya, G et al. (2001) Fusion estrogen receptor proteins: toward the development of receptor-based agonists and antagonists. Mol Cell Endocrinol 182:249-63
Klinge, C M (1999) Estrogen receptor binding to estrogen response elements slows ligand dissociation and synergistically activates reporter gene expression. Mol Cell Endocrinol 150:99-111
Driscoll, M D; Sathya, G; Saidi, L F et al. (1999) An explanation for observed estrogen receptor binding to single-stranded estrogen-responsive element DNA. Mol Endocrinol 13:958-68
Klinge, C M; Studinski-Jones, A L; Kulakosky, P C et al. (1998) Comparison of tamoxifen ligands on estrogen receptor interaction with estrogen response elements. Mol Cell Endocrinol 143:79-90

Showing the most recent 10 out of 26 publications